High-risk myeloma: a gene expression–based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone

Ítems similars

• Cyclophosphamide–bortezomib–dexamethasone compared with bortezomib–dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma
  per: Figueiredo, A., et al.
  Publicat: (2020)
• Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
  per: Ashrafi, Farzaneh, et al.
  Publicat: (2020)
• Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
  per: Hassan Zafar, Mir Sadaqat, et al.
  Publicat: (2018)
• VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma
  per: Pineda-Roman, M, et al.
  Publicat: (2008)
• Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
  per: Shaughnessy, John D., et al.
  Publicat: (2011)